首页> 外文会议>American Control Conference >A robust platform-independent gene signature for single-sample breast cancer subtyping
【24h】

A robust platform-independent gene signature for single-sample breast cancer subtyping

机译:可靠的平台独立基因签名,用于单样本乳腺癌亚型分型

获取原文

摘要

The first step in personalizing therapy for a breast cancer patient is to assign the patient to the appropriate subtype. At present this is done through immunohistochemistry (IHC) which is both expensive as well as wasteful of tumor material. Moreover, error rates can be as high as 20%. In this paper, we propose a new approach to the subtyping of breast cancer patients by using data-driven “reference genes” so that the classification can be carried out for one patient at a time, and across multiple platforms. The validity of the proposed approach is established by training a binary classifier on the TCGA breast cancer data set measured on an Agilent platform, and then applying this classifier to five independent test data sets, on both the Agilent as well as the Affymetrix platforms. In all cases, the results are excellent.
机译:对乳腺癌患者进行个性化治疗的第一步是将患者分配给适当的亚型。目前,这是通过免疫组织化学(IHC)完成的,既昂贵又浪费肿瘤材料。此外,错误率可能高达20%。在本文中,我们提出了一种通过使用数据驱动的“参考基因”对乳腺癌患者进行亚型分型的新方法,以便可以一次针对一个患者并跨多个平台进行分类。通过在安捷伦平台上测量的TCGA乳腺癌数据集上训练二元分类器,然后在安捷伦和Affymetrix平台上将此分类器应用于五个独立的测试数据集,可以确立所提出方法的有效性。在所有情况下,结果都是极好的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号